Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company focusing on the development of treatments for central nervous system (CNS) disorders, particularly major depressive disorder (MDD). The company's lead product candidate, REL-1017, is a new chemical entity (NCE) and NMDA receptor channel blocker. It is currently being evaluated in late-stage clinical trials as an adjunctive treatment for MDD in adults.
REL-1017 has shown promise in clinical studies, demonstrating rapid and sustained improvements in depressive symptoms with a favorable safety profile. The ongoing clinical development program includes two Phase 3 trials: Reliance II (Study 302) and Relight (Study 304), which are designed to assess the efficacy and safety of REL-1017 in patients with MDD who have an inadequate response to their current antidepressant therapies.
Relmada Therapeutics is also advancing a novel non-psychedelic/low dose psilocybin program (REL-P11) for the treatment of metabolic conditions. Initial preclinical studies have shown significant therapeutic potential in improving metabolic parameters, and the company plans to initiate Phase 1 and Phase 2a trials in obese patients with steatotic liver disease.
In recent corporate updates, Relmada has reported significant progress in its clinical development plans, with study enrollments proceeding as expected and additional preclinical and Phase 1 studies supporting future regulatory submissions. The company is well-funded to continue its research and development activities, aiming for multiple clinical milestones and potential regulatory filings in the near future.
Relmada Therapeutics (Nasdaq: RLMD) announced its plan to offer $100 million in common stock through an underwritten public offering. The offering may include an additional 15% of shares, subject to market conditions. Proceeds will fund research and development for REL-1017, a treatment for depression, and for general corporate purposes. Goldman Sachs, Jefferies, and Guggenheim Securities are managing the offering. The offering is made under an existing shelf registration statement. There is no assurance on completion timing or terms.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that data from its human abuse potential study of REL-1017 will be presented at the 60th Annual Meeting of the American College of Neuropsychopharmacology from December 5-8, 2021, in San Juan, Puerto Rico. The poster session is scheduled for December 7, showcasing REL-1017's lack of meaningful opioid abuse liability. REL-1017 is a novel NMDA receptor channel blocker aimed at treating major depressive disorder (MDD). Results from a Phase 2 trial indicated significant antidepressant effects, supporting its late-stage clinical development.
Relmada Therapeutics (Nasdaq: RLMD) provided a corporate update and disclosed financial results for Q3 and YTD 2021. The company's REL-1017 program for treating major depressive disorder is on track, with several key data catalysts expected in 2022. The FDA has confirmed that no additional carcinogenicity or TQT cardiac studies will be required for regulatory approval. Financially, Q3 R&D expenses surged to $34 million, while the net loss for the quarter was $42.6 million or $2.44 per share. As of September 30, 2021, cash and short-term investments stood at $88.1 million.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) announced that CEO Sergio Traversa and CFO Maged Shenouda will present at the Jefferies London Healthcare Conference on November 17, 2021, at 8:00 AM Eastern Time. The event will be accessible via a live webcast, and an archived replay will be available for 90 days. Relmada is focused on advancing REL-1017, a novel NMDA receptor channel blocker in late-stage development for treating major depressive disorder (MDD). The ongoing RELIANCE Phase 3 program aims to evaluate REL-1017's efficacy as a rapid-acting antidepressant.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) will report its third quarter and nine-month financial results after market close on November 11, 2021. A conference call and live audio webcast are scheduled for 4:30 PM Eastern Time on the same day. The company is advancing its lead program, REL-1017, designed for major depressive disorder (MDD). This innovative NMDA receptor channel blocker is in late-stage development, having shown promising results in previous trials.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced the presentation of data on its lead product candidate, REL-1017, at the Neuroscience Education Institute (NEI) Congress on November 5, 2021. The event will feature eight poster presentations and an interactive exhibit booth in Colorado Springs, CO. REL-1017 is being developed for treating major depressive disorder and has shown promising results in clinical trials. Registration is required for virtual and in-person participation.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) announced updates on its late-stage development for REL-1017, a treatment for major depressive disorder (MDD). The new RELIANCE III trial will randomize 364 patients, expected to finish by Q2 2022. The FDA confirmed no two-year carcinogenicity study is required, and existing data is sufficient for assessing cardiac safety in regulatory submissions. REL-1017 has shown promising results in previous trials, indicating potential for rapid, effective treatment of MDD.
Relmada Therapeutics (NASDAQ: RLMD) announced that CEO Sergio Traversa will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 12:25 PM ET. Attendees can access a live webcast of the event here or through the Relmada website. The company is advancing REL-1017, a novel NMDA receptor channel blocker, in late-stage development for major depressive disorder (MDD), demonstrating promising results in Phase 2 trials. An archived replay will be available for 90 days post-event.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) announced that CEO Sergio Traversa will present at the 19th Annual Morgan Stanley Global Healthcare Conference on September 10, 2021, at 12:30 PM ET. A live webcast of the event will be available, and participants can access it through the provided link. Relmada's lead program, REL-1017, is a novel NMDA receptor blocker in late-stage development for major depressive disorder (MDD), showing promising results in Phase 2 trials with significant improvements over placebo. An archived replay will be available post-presentation.
Relmada Therapeutics (Nasdaq: RLMD) reported financial results for Q2 and the first half of 2021. The pivotal Phase 3 RELIANCE program for REL-1017 is progressing, with a successful human abuse potential study showing significant safety results. The company also acquired rights to a novel psilocybin program, enhancing growth prospects. In Q2, R&D expenses surged to $17.3 million, contributing to a net loss of $26.6 million or $1.56 per share. Cash reserves stood at $109.1 million as of June 30, 2021, down from $117.1 million at year-end 2020.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
What is Relmada Therapeutics' primary focus?
What is REL-1017?
What are Reliance II and Relight?
What recent progress has Relmada reported?
What is the REL-P11 program?
How has REL-1017 performed in clinical studies?
What are the anticipated milestones for Relmada in 2024?
Is Relmada financially stable to continue its research?
What is the significance of REL-1017's mechanism of action?
How can I learn more about Relmada Therapeutics?
